Trial Profile

A Phase 1/2a, Randomized, Double-blind, Placebo-controlled Study of Ascending Doses of WVE-007 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adults Living With Overweight or Obesity

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 06 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Jul 2026 According to a Wave Life Sciences media release, dosing is underway in the Phase 2a multidose portion of the INLIGHT trial.
30 Jul 2026 According to a Wave Life Sciences media release, an additional data from the INLIGHT trial, including data from the 600 mg Phase 1 SAD cohort, are expected in the second half of 2026.
24 Jun 2026 According to a Wave Life Sciences media release, company announced it has initiated the Phase 2a multidose portion of this trial. The Phase 2a portion of the INLIGHT trial is expected to enroll participants across the U.S. and Europe.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com